Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance

AstraZeneca plcTrade
iShares Core MSCI EAFE ETFTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs iShares Core MSCI EAFE ETF — how do they compare? AstraZeneca plc trades at $158.17 (market cap $248.14B), while iShares Core MSCI EAFE ETF trades at $100.97. The key difference: AstraZeneca plc pays a 2.01% dividend while iShares Core MSCI EAFE ETF pays none, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.

AZNIEFA
Market Cap
$248.14B
Sector
HealthBroad Market / Factor
52-Week High
$209.48$101.09
52-Week Low
$147.06$84.72
Enterprise Value
$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.

The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.

iShares Core MSCI EAFE ETF

IEFA trades at $101.28, up 0.75% today, with a bullish technical outlook from moving averages but overbought RSI signals. The ETF focuses on developed international markets excluding the U.S. and Canada, offering diversification and a dividend yield. Recent news highlights its role in defensive portfolio shifts and comparisons with peers like VXUS and SPGM.

Outlook is positive for diversification seekers amid U.S. concentration risks, supported by lower fees and income appeal. Risks include developed-market economic sensitivity and currency fluctuations. Analyst sentiment is generally favorable for long-term exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About iShares Core MSCI EAFE ETF

IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.

Read more on IEFA